Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial

Fig. 3

The live-virus neutralizing antibody titers, along with the corresponding fourfold rise rate, against prototype SARS-CoV-2 strain and Omicron BA.1.1 variant induced by the booster vaccination of NVSI-06-09, compared with those boosted with BBIBP-CorV. a The anti-prototype and anti-Omicron BA.1.1 neutralizing antibody titers at baseline and on day 14 after booster vaccination. Data are presented as GMTs and 95% CIs. b The corresponding fourfold rise rate of neutralizing antibodies from baseline and 95% CIs on day 14 after booster. ****: p < 0.0001, ns not significant

Back to article page